Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

J. Wang; S. V. Liu; H. E. Uronis; C. Wu; D. Mahalingam; A. Spira; L. Carter; X. Hu; G. Weems; H. J. Wilkins; L. R. Duska; K. Kelly

doi:10.1093/annonc/mdy288.012

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

J. Wang, S. V. Liu, H. E. Uronis, C. Wu, D. Mahalingam, A. Spira, L. Carter, X. Hu, G. Weems, H. J. Wilkins, L. R. Duska, K. Kelly

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii404-viii405
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy288.012
State	Published - Oct 1 2018
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy288.012

Cite this

Wang, J., Liu, S. V., Uronis, H. E., Wu, C., Mahalingam, D., Spira, A., Carter, L., Hu, X., Weems, G., Wilkins, H. J., Duska, L. R., & Kelly, K. (2018). Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii404-viii405. https://doi.org/10.1093/annonc/mdy288.012

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716 : Safety and efficacy in a phase IIA open-label, multicenter trial. / Wang, J.; Liu, S. V.; Uronis, H. E.; Wu, C.; Mahalingam, D.; Spira, A.; Carter, L.; Hu, X.; Weems, G.; Wilkins, H. J.; Duska, L. R.; Kelly, K.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii404-viii405.

Research output: Contribution to journal › Article › peer-review

Wang, J, Liu, SV, Uronis, HE, Wu, C, Mahalingam, D, Spira, A, Carter, L, Hu, X, Weems, G, Wilkins, HJ, Duska, LR & Kelly, K 2018, 'Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii404-viii405. https://doi.org/10.1093/annonc/mdy288.012

Wang, J. ; Liu, S. V. ; Uronis, H. E. ; Wu, C. ; Mahalingam, D. ; Spira, A. ; Carter, L. ; Hu, X. ; Weems, G. ; Wilkins, H. J. ; Duska, L. R. ; Kelly, K. / Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716 : Safety and efficacy in a phase IIA open-label, multicenter trial. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii404-viii405.

@article{1a9ccb3ffc1c4555b375fe0d2e01db6c,

title = "Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial",

author = "J. Wang and Liu, {S. V.} and Uronis, {H. E.} and C. Wu and D. Mahalingam and A. Spira and L. Carter and X. Hu and G. Weems and Wilkins, {H. J.} and Duska, {L. R.} and K. Kelly",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy288.012",

language = "English (US)",

volume = "29",

pages = "viii404--viii405",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716

T2 - Safety and efficacy in a phase IIA open-label, multicenter trial

AU - Wang, J.

AU - Liu, S. V.

AU - Uronis, H. E.

AU - Wu, C.

AU - Mahalingam, D.

AU - Spira, A.

AU - Carter, L.

AU - Hu, X.

AU - Weems, G.

AU - Wilkins, H. J.

AU - Duska, L. R.

AU - Kelly, K.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081967718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081967718&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy288.012

DO - 10.1093/annonc/mdy288.012

M3 - Article

C2 - 32137012

VL - 29

SP - viii404-viii405

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -